

**MultiPark Board Meeting**

2023-11-21, 13:00-15:00, via Zoom

Minutes

Participating Board members:

Angela Cenci Nilsson

Oskar Hansson (-14:40)

Kajsa M Paulsson

Roger Olsson (13:50-)

David Gisselsson Nord

Martin Hallbeck

Divya Bali

Radhika Thakore

Absent Board members:

Stefan Jovinge

José Luis Molinuevo

Madeleine Durbeej-Hjalt

Others present:

Diana Jerman (meeting secretary)

§1. Designation of minute reviewer

Oskar Hansson was assigned together with the coordinator Angela Cenci Nilsson to review the minutes.

§2. Approval of the agenda

The Board approved the agenda.

§3. Declaration of conflicts of interest

Roger Olsson left the meeting during the discussion and decision on the budget item “Drug candidate screening platform” due to conflict of interest.

Oskar Hansson left the meeting during the discussions and decisions on the Stem-PD project and Translational Cell Therapy due to conflict of interest.

§4. Approval of the minutes from the previous Board meeting 2023-09-26

The Board approved the minutes from the previous Board meeting on 2023-09-26.

§5. Approval of the delegated decisions

The Board approved the delegated decisions summarized in enclosure 2.

The Board pointed out that the budget currently allocated to travel grants (1 MSEK in 2023) is quite high. The Board emphasised that PhD students and post-docs should exploit all available sources to get travel grants from both private Foundations and

Faculties. Information about other sources of travel grant support should be posted on the MultiPark website and possibly also included in the travel grant application form. The maximum amount awarded per applicant per year should be decreased.

§6. Brief review of the requested information package about MultiPark, including Board roles and expectations

The coordinator summarized the information package about MultiPark, including expectations on the Board. The presentation was well received.

§7. Summary of the Infrastructure and project evaluations carried out during the autumn

The process was described to the Board. Briefly, reports about infrastructures and projects, and the corresponding budget applications were submitted to Linda Eliasson by November 1. Linda Eliasson prepared a written evaluation of each infrastructure and project with focus on highlighting aspects that require improvement and/or discussion (sent on November 16 to the coordinators and to Kajsa Paulsson). The applications for infrastructure support were discussed at the Steering group meeting on November 10 after presenting a budget prognosis for 2024. The steering group agreed that an effort should be made not to increase the overall budget allocation to infrastructures in order to keep a portion of the budget available for dynamic initiatives.

§8. Principles for budget allocation and decisions on the MultiPark budget 2024

The Board decided on the following general principles for the funding of infrastructures and projects:

- MultiPark does not have any legal obligation to support any infrastructure or project for a longer period than indicated in the decision letter that is communicated to the awardee.
- Funding to infrastructures is conditional on a sufficient adherence to the “Conditions for infrastructure support by MultiPark” (document posted on our webpage under Research > Infrastructures).
- MultiPark is to bind oneself to longer than 1 year funding only in relation to well-functioning and stable infrastructures having clear strategic importance for the MultiPark research programme. Even if support is awarded for longer than 1 year, the exact budget allocated to the awarded items will be confirmed by MultiPark one year at a time.
- The normal procedure for funding projects is via open calls subject to review by EAB members and other experts where appropriate. MultiPark-supported projects should be presented to our network during the MultiPark retreats and other open events.
- The standard duration of project support by MultiPark is 2 years. Standard project grants amount to 250 000-500 000 SEK/year (including indirect costs), the final sum

being conditional on the funding available in relation to the number of projects to be supported in each specific call.

Decisions on the budget 2024

The total available budget for 2024 (excluding earmarked carried-over funds) is estimated to be lower than that available in 2023. This is due to a lower amount of unspent funds that can be carried over from this year to the next, but also due to a large raise in salary costs and lab/room rents from next year.

The Board made an *en bloc* **decision** to approve the budget items marked in grey in the enclosed budget file (see enclosure 1).

However, the budget items/proposals marked in light yellow in the budget file were discussed in detail and were not approved as submitted. These budget items/proposals are listed and commented upon below:

Infrastructures:

- "Next generation sequencing (NGS)":

While reviewing the budget spent on experimental infrastructures, questions were raised regarding the MultiPark support to the NGS platform, in consideration that there is another infrastructure, Centre for Translational Genomics (CTG), where services for single-cell sequencing and bioinformatic analysis are provided.

It was therefore **decided** that Kajsa Paulsson will organise a meeting with the managers of the MultiPark NGS platform and the CTG. This meeting aims to explore models of collaboration opportunities with CTG that are cost-efficient for MultiPark. A final decision on the exact levels of support provided by MultiPark to the NGS platform will be made subsequent to this discussion.

- "AI/ML knowledge base"

It was **decided** that support will be provided conditional on the presentation of an outreaching plan with measurable milestones. The plan will be reviewed by the MultiPark management and Kajsa Paulsson.

- "In vivo brain circuit analysis platform"

It was **decided** that support will be provided conditional on the presentation of an outreaching plan with measurable milestones. The plan will be reviewed by the MultiPark management and Kajsa Paulsson.

- "Drug candidate screening platform"

It was **decided** that support will be provided conditional on (1) that the sponsorship given by MultiPark is acknowledged in the Faculty website where this infrastructure is described as the "CBT Small Molecule Screening infrastructure"; (2) that the infrastructure description on the MultiPark website is substantially improved (more information is needed on the specific services provided and how to access them); (3) that a plan of outreach is prepared to increase the number of MultiPark users. The requested improvements and the outreaching plan will be reviewed by the MultiPark management and Kajsa Paulsson.

Projects:

- “Translational Cell Therapy”:

It was **decided** to support a call for Translational Cell & Gene Therapy projects according to a procedure similar to that used in 2023 to fund Translational pharmacology projects (i.e., with 500 000 SEK/year allocated to selected projects for 2 years, 2024 and 2025). It was moreover suggested to involve the Head of the new preclinical ATMP centre (“Pre-GMP centre”) in the review process.

It was **decided** that 25% salary support is to be provided for Jenny Nelander in 2024 while phasing out the “Translational Cell Therapy Platform”¹. It was suggested that Jenny Nelander continues to help in the STEM-PD project for the time paid by MultiPark.

- “Stem-PD”:

The application for a 50% research nurse salary for the Stem-PD clinical trial was reviewed, and the correspondence related to Stem-PD was summarized. It was **decided** that further MultiPark support to the Stem-PD trial is conditional on an expert review of the project’s costs, including:

- Verification of the actual expenses incurred for the cell handling costs in Lund (cf. Gesine Paul-Visse’s application 2022).
- Perusal of both the original project budget, and an updated budget where the actual expense increases are itemized (particularly for the personnel).
- Information on the outcome of ongoing discussions with NovoNordisk aiming at obtaining support for unanticipated costs.

It was **decided** that the review process will be led by Stefan Jovinge, our Board Member and Research Director at Skåne University Hospital.

§9. Overview of the MultiPark leadership structure in the next mandate period 2024-2026

An overview of the Board composition in 2024 was presented. The current Board members have a mandate until 2025.

Changes relative to 2023 are the following:

José Luis Molinuevo will step down due to lack of time. Oskar Hansson will be replaced by the two new vice-coordinators Maria H Nilsson and Per Odin. David Gisselsson Nord may be replaced by other member of the Medical Faculty management.

§10. Other points

It was suggested to compare the composition of Management vs. Board currently used in MultiPark to that used by other SRAs at Lund university, particularly within the Medical Faculty.

NOTE ADDED AFTER THE MEETING:

The allocation of infrastructure funds for years 2025-2026 could not be discussed due to lack of time. This decision is to be taken by the MultiPark Board next year based on the

¹ This support will not continue beyond 2024 (being replaced by support to Translational Cell & Gene Therapy projects).

applications received this Autumn, the evaluations carried out by Linda Eliasson, intervening discussions with Kajsa Paulsson (cf. §8), and discussions that will take place during the steering group meetings.



Angela Cenci Nilsson
Coordinator of MultiPark

Oskar Hansson
Vice-coordinator of MultiPark



Diana Jerman
Meeting secretary

Appendix - Budget for 2024

| | BUDGET 2024 |
|--|--------------------|
| BUDGET MULTIPARK | EMV OH 25% |
| Income | 31 532 000 |
| Rent subvention | 869 000 |
| Balance from previous year 2023 (estimated unspent funds) | 1 100 000 |
| Earmarked funds carried over from 2023 (Task-force, Phamacology grant, Spectroscopy procurement) | 1 690 000 |
| Income total | 35 191 000 |
| A - Management | |
| Coordinator salary "intrångsersättning" (35%) | 680 456 |
| Vice-ordinators salary "intrångsersättning" (10%) Per Odin | 173 755 |
| Vice-ordinators salary "intrångsersättning" (10%) Maria H Nilsson | 141 437 |
| Communications officer (50%) | 511 426 |
| Research administrator salary (100%) | 894 066 |
| Infrastructre manager (50%) | 584 486 |
| Rent administration office (50% of A1349) L Eliasson | 41 587 |
| Remuneration EAB members | 100 000 |
| Management (meetings, computers) | 100 000 |
| Rent administration office (I1319a+B1109b (25%)) | 126 392 |
| BMC service | 500 465 |
| Management Sum | 3 854 071 |
| B - Education, Networking, Outreach | |
| Study Coordinator (10%) Tomas Deierborg | 210 019 |
| Graduate School seminars | 30 000 |
| New course organised by vice-coordinator Maria H Nilsson | 150 000 |
| MultiPark annual retreat | 400 000 |
| Travel grants | 900 000 |
| Other strategic grants | 200 000 |
| Network enhancing activities (Young MPs, Parkinson Skåne, Frontiers seminar) | 350 000 |
| Education, Networking, Outreach Sum | 2 240 019 |
| C - Positions: permanent | |
| Professor Salary; Experimental (72%) Gunnar Gouras | 1 158 353 |
| Professor Salary; Experimental (72%) Roger Olsson | 1 174 045 |
| Professor Salary, Neurology (70%) Per Odin | 996 957 |
| Professor salary, Health science (36%) Jan Lexell | 552 658 |
| Lektor salary, Health science (70%) Maria H Nilsson | 804 928 |
| Positions Sum | 4 686 940 |
| C - Positions: recruitment/career positions | |
| Salary or start-up package for young research group leaders | 1 000 000 |
| Positions Sum | 1 000 000 |
| D - Jointly funded infrastructures and HR platforms | |
| Statistical cost (Region Skåne) | 150 000 |
| MSD platform, lab rent (C1123a) | 71 854 |
| MDS equipment service | 168 750 |
| Jointly funded Infrastructures and HR platforms Sum | 390 604 |
| E - Strategic project support | |
| Innovation grants (prel 2 project grants) | 500 000 |
| Translational Pharmacology projects (2 grants, Oct 2023-Sept 2025; 500 000 SEK carried over from 2023) | 1 000 000 |
| Translational Cell & Gene Therapy projects | 500 000 |
| Translational Cell Therapy platform (25% pre-clinical coordinator Jenny Nelander) | 280 515 |
| STEM-PD (50% clinical project coordinator Trinette van Vliet) | 421 900 |
| Strategic project support Sum | 2 702 415 |
| Total jointly funded budget Sum: | 14 874 050 |
| Balance (i.e., total income minus total jointly funded costs) | 20 316 950 |
| <i>Balance is divided between</i> | |
| <i>Experimental node (55% of the balance)</i> | 11 174 323 |
| <i>Clinical / Health science node (45% of the balance)</i> | 9 142 628 |

ALL SUMS INCLUDE OH (LU-EMV 2025 = 25%) except the Professor salaries for G Gouras, R Olsson, P Odin, J Lexell and lector salary M Nilsson

2024

| Experimental Infrastructure and HR platforms | | 11 174 323 |
|--|-------------------|--------------------|
| FACS / Operetta | | |
| Research Engineer (100%) Anna Hammarberg: FACS, Operetta, Plate Runner | 1 089 720 | |
| Service contract FACS | 204 930 | |
| Service contract Operetta | 205 000 | |
| Booking system Infinity X for FACS & Operetta. Licence fee and initial training and implementation | 72 480 | |
| Rent Operetta, FACS, Azure Sapphire, Imaris, RE office (B1135a, B1128a, B1128b, B1155a) | 742 534 | |
| FACS / Operetta Sum | 2 314 664 | |
| Cell and Gene Therapy Core (CAGT) & Bacteria lab & Retroviral production | | |
| Cell and Gene Therapy Core, research engineer (50%) Beata Lindqvist | 495 327 | |
| Cell and Gene Therapy Core; Development of improved AAV procedures | 55 000 | |
| Bacteria lab & Retroviral production, research engineer (40%) Marie Persson-Vejgård | 366 542 | |
| Bacteria lab & Retroviral production, rent of lab (A1119) | 75 787 | |
| Cell and Gene Therapy Core (CAGT) / & Bacteria lab Sum | 992 657 | |
| Next Generation Sequencing | | |
| Next Generation Sequencing, research engineer (50%) Jenny G Johansson | 474 276 | Decision postponed |
| Next Generation Sequencing, Rent of lab (B1113a) | 206 580 | Decision postponed |
| Next generation sequencing, Bioinformatics (50%), Yogita Sharma | 600 585 | Decision postponed |
| Next generation sequencing Sum | 1 281 441 | |
| Advanced Microscopy Platforms | | |
| Two-photon microscopy, expert salary (10%), Karsten Ruscher | 150 000 | |
| Two-photon ex vivo rent F0936 (50%), Two-photon in vivo rent C0972b & C0974a | 314 520 | |
| Two-photon Equipment service (MP and NLO system) | 125 000 | |
| Two-photon Equipment upgrading and repair (NLO system) | 100 000 | |
| Confocal microscope A10 rent A1054 (50%) | 75 942 | |
| Confocal, Live cell imaging and Image analysis, assisting PhD student Emma Nyberg (20% Jan-Feb) | 26 335 | |
| Research engineer with microscopy and 3D image expertise, (50% Feb-Dec) | 488 104 | |
| Advanced Microscopy Platforms Sum | 1 279 901 | |
| In vivo core facility | | |
| Mouse node: A0938 (33%), A0932 (33%), A0934 (100%), Platform manager Elena Espa 20%, IT Nyström | 332 298 | |
| Rat node: A0931, A0932 (67%), A0958, A0938 (33%), Platform manager Susanne Geres (15%) | 404 452 | |
| Terminal: rent A0955, A0954, A0938 (34%), Platform manager Susanne Geres (15%) | 339 130 | |
| In vivo core facility Sum | 1 075 880 | |
| AI/ML knowledge base | | |
| Coordinator, Pär Halje (20%) | 230 327 | Decision postponed |
| Drug candidate screening platform | | |
| Researcher, Fredrik Ek (25%) | 343 014 | Decision postponed |
| MP & StemTherapy joint electrophysiology core facility | | |
| Research engineer Claire Piochon (80%, 12 months) | 812 337 | |
| Rent F0936 (50%), F0938 | 325 118 | |
| Equipment upgrading /replacement of damaged parts | 200 000 | |
| Electrophysiology core facility Sum | 1 337 455 | |
| In vivo brain circuit analysis platform | | |
| Platform manager Andreas Heuer 50% | 853 202 | Decision postponed |
| Rent lab C1060a | 68 820 | Decision postponed |
| In vivo brain circuit analysis platform Sum | 922 022 | |
| Funds carried over from 2023 to 2024 | | |
| Task-force on Synchrotron-based molecular imaging (June 2022-May 2024) | 240 000 | |
| Transgenic rodent resource | 87 500 | |
| Infrared spectroscopy at the nano-scale (procurement ongoing) | 950 000 | |
| Total Experimental Science | 11 054 861 | |
| Balance (Experimental) | 119 462 | |

ALL SUMS INCLUDE OH (LU-EMV 2024 = 25%)

2024

| | |
|--|------------------|
| Clinical & Health Science Infrastructures and HR platforms | 9 142 628 |
| Clinical Parkinson Research Platform | |
| Research nurses/research assistant nurses, a total of 250% | 1 710 500 |
| Medical Doctor, Sotirios Grigoriou (40%) | 550 000 |
| Clinical Parkinson Research Platform Sum | 2 260 500 |
| Memory and Neurosurgery platform | |
| Research nurses, Memory Clinic (200%) | 1 891 248 |
| Study coordinator, Memory Clinic (50%), Joanna Grzegorska | 437 348 |
| Research physician, Memory Clinic (70%) | 579 204 |
| Research nurse, Neurosurgery (25%) | 289 540 |
| Memory and Neurosurgery Sum | 3 197 340 |
| Neuroimaging | |
| Laboratory researcher, MR Data analysis and management, Olof Strandberg (50%) | 500 000 |
| Researcher at Diagnostic Radiology, Pipeline development (likely Samo Lasic) | 200 000 |
| Neuroimaging Sum | 700 000 |
| Simoa platform | |
| Service contract, equipment service Simoa | 163 750 |
| Research engineer Simoa platform. Pilar Lorenzo (50%) | 505 500 |
| Rent C1121a (50%) | 49 687 |
| Simoa platform Sum | 718 937 |
| Bioinformatics; genetics | |
| Bioinformatician Joel Wallenius, 20% | 223 000 |
| Bioinformatician, medical geneticist, 15%, Efthymia Kafantari | 134 000 |
| Lab rent | 10 000 |
| Equipment upgrading | 8 000 |
| Bioinformatics; genetics Sum | 375 000 |
| SweTRAP, Swedish Trial Ready Cohorts for early AD and PD | |
| Research nurse or BMA, 100% | 945 630 |
| Research physician, 50% | 413 670 |
| SweTrap Sum | 1 359 300 |
| United Neuroscience Campus (Rostock-Lund program), administrative support | 161 300 |
| Total Clinical Science/HCS | 8 772 377 |
| Balance (Clinical/HCS) | 370 251 |

ALL SUMS INCLUDE OH (LU-EMV 2024 = 25%)